Trial · NCT05093478
The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population
NCT05093478, Phase 3, Completed, The University of Texas Health Science Center, Houston; results first posted 2024-12-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population. Trials, record NCT05093478. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05093478
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population
- NCT number
- NCT05093478
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 28 participants, actual
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Conditions
- Non-allergic Rhinitis
- Interventions
- Intranasal capsaicin, topical lidocaine
- First posted
- 2021-10-26
- Last updated
- 2024-12-20
- Results first posted
- 2024-12-20
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Runny Nose as Measured by the Visual Analog Scale (VAS) at Baseline | baseline | The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable. |
| Primary | Runny Nose as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment | 4 weeks post treatment | The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable. |
| Primary | Runny Nose as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment | 12 weeks post treatment | The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable. |
| Primary | Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at Baseline | baseline | The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable. |
| Primary | Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment | 4 weeks post treatment | The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable. |
| Primary | Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment | 12 weeks post treatment | The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable. |
| Primary | Nasal Itching as Measured by the Visual Analog Scale (VAS at Baseline | baseline | The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable. |
| Primary | Nasal Itching as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment | 4 weeks post treatment | The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable. |
| Primary | Nasal Itching as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment | 12 weeks post treatment | The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable. |
| Primary | Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at Baseline | baseline | The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Runny Nose as Measured by the Visual Analog Scale (VAS) at Baseline | baseline | score on a scale | MEAN | |
| PRIMARY | Runny Nose as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment | 4 weeks post treatment | score on a scale | MEAN | |
| PRIMARY | Runny Nose as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment | 12 weeks post treatment | score on a scale | MEAN | |
| PRIMARY | Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at Baseline | baseline | score on a scale | MEAN | |
| PRIMARY | Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment | 4 weeks post treatment | score on a scale | MEAN | |
| PRIMARY | Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment | 12 weeks post treatment | score on a scale | MEAN | |
| PRIMARY | Nasal Itching as Measured by the Visual Analog Scale (VAS at Baseline | baseline | score on a scale | MEAN | |
| PRIMARY | Nasal Itching as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment | 4 weeks post treatment | score on a scale | MEAN | |
| PRIMARY | Nasal Itching as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment | 12 weeks post treatment | score on a scale | MEAN | |
| PRIMARY | Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at Baseline | baseline | score on a scale | MEAN |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 outcomesResults by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Runny Nose as Measured by the Visual Analog Scale (VAS) at Baseline | Treatment | 6.07 | Standard Deviation 2.41 | score on a scale | |
| Runny Nose as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment | Treatment | 2.89 | Standard Deviation 2.04 | score on a scale | |
| Runny Nose as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment | Treatment | 3.75 | Standard Deviation 3.15 | score on a scale | |
| Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at Baseline | Treatment | 5.57 | Standard Deviation 2.80 | score on a scale | |
| Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment | Treatment | 2.46 | Standard Deviation 2.13 | score on a scale | |
| Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment | Treatment | 2.75 | Standard Deviation 2.13 | score on a scale | |
| Nasal Itching as Measured by the Visual Analog Scale (VAS at Baseline | Treatment | 2.25 | Standard Deviation 2.60 | score on a scale | |
| Nasal Itching as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment | Treatment | 1.50 | Standard Deviation 1.95 | score on a scale | |
| Nasal Itching as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment | Treatment | 1.20 | Standard Deviation 1.84 | score on a scale | |
| Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at Baseline | Treatment | 3.03 | Standard Deviation 2.47 | score on a scale |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment | 28 | |
| Overall Study | COMPLETED | Treatment | 24 | |
| Overall Study | NOT COMPLETED | Treatment | 4 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment | 0 | 28 |
| Total, other adverse events | Treatment | 0 | 28 |
| Total, serious adverse events | Treatment | 0 | 28 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05093478
GET https://conductscience.org/api/trials/v1/NCT05093478/registered